- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03597555
Sodium Oxybate in Idiopathic Hypersomnia (SODHI)
A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Bicentric, randomized, double-blind controlled study Outpatients aged from 18 to 60 years, suffering from current idiopathic hypersomnia (ICSD-3), recruited via medical consultations in the investigation centers Randomization in Xyrem or placebo arms after the inclusion visit,
1.Screening Period (up to 15 days), 2.Titration Period (up to 45 days), 3.Maintenance Period (minimum 15 days), 4.Safety Follow-Up Period (14 days)
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Yves DAUVILLIERS, Pr
- Phone Number: 33 4 67 33 63 61
- Email: y-dauvilliers@chu-montpellier.fr
Study Locations
-
-
-
Montpellier, France
- University Hospital of Montpellier
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnostic of idiopathic hypersomnia (ICSD-3 criteria)
- Age between 18 and 60 years-old
- BMI between 18 and 35 kg/m2
- MSLT: mean sleep latency (MSL) ≤8 minutes and < 2 SOREMPs, AND/OR total sleep time > 11h/24h on 24-hours long-term polysomnography
- Polysomnography recording: sleep efficiency > 85%, total sleep time ≥6 hours, AHI <10/hour, micro-arousals index <15/hour, PLM index associated with micro-arousals <10/hour.
- Absence of sleep deprivation, assessed by actigraphy or sleep logs
- ESS score ≥14 points
- Written informed consent
- National health insurance cover
Exclusion Criteria:
Current alcohol intake or treatment with modafinil, amphetamine, methylphenidate, mazindol, pitolisant, neuroleptics, sedative hypnotics, barbiturates, general anesthetics, myorelaxants, other CNS depressants, antidepressants*, anxiolytic drugs, anticonvulsive therapy, topiramate, inhibitors of GHB dehydrogenase (i.e. valproate, ethosuximide, phenytoin), budipine, dopamine antagonist antiemetics (except domperidone), opioids, benzodiazepines, Z-drugs, MAO inhibitors, COMT inhibitors, or sedative antihistamines. If patient has received such therapy, a washout-period of at least 15 days, or equivalent to 5 half-lives of the drug, prior to the inclusion in the study is required before starting treatment in this study.
*30 days for antidepressants
- Previous intake of sodium oxybate
- Succinic semialdehyde dehydrogenase deficiency, porphyria
- Other central nervous system diseases: neurodegenerative diseases, seizure disorders or history of head trauma associated with loss of consciousness
- Lifetime history of suicide attempt or suicidal ideation in the past 6 months, prior history of psychotic episodes, current or recent history of a major depressive disorder (DSM-V), Beck depression inventory (BDI) > 16 and/or item G> 0
- History of chronic alcohol or drug abuse within the prior 12 months
- Malignant neoplastic disease requiring therapy within 12 months prior to Visit 1 or clinically relevant
- Heart failure, severe hypertension or other cardiovascular disease compromising the patient's wellbeing or ability to participate in this study
- Renal or hepatic impairment Compromised respiratory function
- Sleep-related breathing disorders (AHI ≥ 10/h)
- No regular sleep at night: shift work or other continuous non-disease-related life conditions
- Participation in another study of an investigational drug within the 28 days prior to Visit 1 or currently
- Hypersensitivity to any of the components of the study medication
- Pregnancy (βHCG positive) and breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Xyrem
Xyrem (Sodium Oxybate), oral solution 500mg/mL First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks. First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period. First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal |
First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks. First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period. First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal |
Placebo Comparator: Placebos
Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
|
Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Epworth Sleepiness Scale (ESS) score at the end-point visit
Time Frame: over 8 weeks
|
Evaluation of difference in sleepiness with ESS between the 2 groups.
ESS scores range from 0 to 24; there is a risk of pathological daytime sleepiness if score is > 10.
|
over 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yves DAUVILLIERS, University Hospital, Montpellier
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Disorders of Excessive Somnolence
- Idiopathic Hypersomnia
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Adjuvants, Anesthesia
- Sodium Oxybate
Other Study ID Numbers
- RECHMPL17_0375
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Hypersomnia
-
Lynn Marie TrottiGeorgia Research AllianceCompletedIdiopathic Hypersomnia | Hypersomnia | Narcolepsy Without Cataplexy | Primary HypersomniaUnited States
-
Centre d'Investigation Clinique et Technologique...Completed
-
Millennium Pharmaceuticals, Inc.CompletedA Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic HypersomniaIdiopathic HypersomniaUnited States, Japan
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
Northwestern UniversityCompletedNarcolepsy | Idiopathic HypersomniaUnited States
-
Centre Hospitalier Universitaire de Saint EtienneCompletedNarcolepsy | CataplexyFrance
-
University Hospital, Strasbourg, FranceNot yet recruiting
-
Mayo ClinicRecruiting
-
Harmony Biosciences, LLCCompletedIdiopathic HypersomniaUnited States
Clinical Trials on Sodium Oxybate Oral Solution 500 MG/ML
-
Jazz PharmaceuticalsCompleted
-
Jazz PharmaceuticalsCompleted
-
Brigham and Women's HospitalWithdrawnTraumatic Brain Injury | Narcolepsy | HypersomniaUnited States
-
Jazz PharmaceuticalsCompletedTrial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of FibromyalgiaFibromyalgiaUnited States
-
Taipei Medical UniversityCompleted
-
AstraZenecaCompletedSafety, Pharmacokinetics, Pharmacodynamics, Food EffectUnited Kingdom
-
Galapagos NVCompleted
-
PepsiCo Global R&DCompleted
-
Richever Enterprise Co., Ltd.UnknownGalactose Single Point (GSP), Residual Liver Function
-
Christian Medical College and Hospital, Ludhiana...All India Institute of Medical Sciences, New Delhi; Indian Council of Medical... and other collaboratorsRecruitingIntracerebral Hemorrhagic StrokeIndia